Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.
At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.
While gastrointestinal symptoms seem to be the most common, a laundry list of others have been discussed in the news, on TikTok, and across online forums.
Steve Greene, MD, discusses the results of a TRANSFORM-HF analysis comparing the effects of furosemide and torsemide on quality of life outcomes in patients with heart failure.
“The Heart in Diabetes (HiD) conference, entering its seventh year, is a renowned medical meeting that brings together global clinical leaders in diabetes, obesity and cardiorenal metabolic diseases together with practicing clinicians to improve the care of patients at a high risk of these comorbidities. This is a unique and exciting multidisciplinary program: Where the Heart, Kidney, and